ABSTRACT
In present paper, an expeditious total synthesis of naturally occurring 5'-deoxytoyocamycin and 5'-deoxysangivamycin was accomplished. Because of the introduction of a benzoyl group at N-6 of 4-amino-5-cyano-6-bromo-pyrrolo[2,3-d]pyrimidine, a Vorbrüggen glycosylation with 1,2,3-tri-O-acetyl-5-deoxy-ß-D-ribofuranose afforded a completely regioselective N-9 glycosylation product, which is unambiguously confirmed by X-ray diffraction analysis. All of the involved intermediates were well characterized by various spectra.
Subject(s)
Pyrimidine Nucleosides/chemical synthesis , Toyocamycin/analogs & derivatives , Glycosylation , Models, Molecular , Molecular Structure , Pyrimidine Nucleosides/chemistry , Toyocamycin/chemical synthesis , Toyocamycin/chemistryABSTRACT
Human equilibrative nucleoside transporterâ 1 (hENT1) is a prototypical nucleoside transporter protein ubiquitously expressed on the cell surface of almost all human tissue. Given the role of hENT1 in the transport of nucleoside drugs, an important class of therapeutics in the treatment of various cancers and viral infections, efforts have been made to better understand the mechanisms by which hENT1 modulates nucleoside transport. To that end, we report here the design and synthesis of novel tool compounds for the further study of hENT1. The 7-deazapurine nucleoside antibiotic tubercidin was converted into its 4-N-benzyl and 4-N-(4-nitrobenzyl) derivatives by alkylation at N3 followed by a Dimroth rearrangement to the 4-N-isomer or by fluoro-diazotization followed by SN Ar displacement of the 4-fluoro group by a benzylamine. The 4-N-(4-nitrobenzyl) derivatives of sangivamycin and toyocamycin antibiotics were prepared by the alkylation approach. Cross-membrane transport of labeled uridine by hENT1 was inhibited to a weaker extent by the 4-nitrobenzylated tubercidin and sangivamycin analogues than was observed with 6-N-(4-nitrobenzyl)adenosine. Type-specific inhibition of cancer cell proliferation was observed at micromolar concentrations with the 4-N-(4-nitrobenzyl) derivatives of sangivamycin and toyocamycin, and also with 4-N-benzyltubercidin. Treatment of 2',3',5'-O-acetyladenosine with aryl isocyanates gave the 6-ureido derivatives but none of them exhibited inhibitory activity against cancer cell proliferation or hENT1.
Subject(s)
Antineoplastic Agents/chemical synthesis , Cell Proliferation/drug effects , Equilibrative Nucleoside Transporter 1/antagonists & inhibitors , Purine Nucleosides/chemical synthesis , Purines/chemical synthesis , Pyrimidine Nucleosides/chemical synthesis , Pyrimidine Nucleosides/pharmacology , Toyocamycin/analogs & derivatives , Alkylation , Antibiotics, Antineoplastic/chemistry , Antibiotics, Antineoplastic/pharmacology , Antineoplastic Agents/pharmacology , Cell Line, Tumor , Humans , Membrane Transport Modulators/chemical synthesis , Membrane Transport Modulators/pharmacology , Toyocamycin/chemical synthesis , Toyocamycin/pharmacology , Tubercidin/chemistry , Tubercidin/pharmacologyABSTRACT
In the course of our screening for novel modulators on cell cycle progression and apoptosis as anticancer drug candidates, we generated an analogue of sangivamycin, MCS-C2, designated as 4-amino-6-bromo-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide. This study was aimed to evaluate the molecular mechanisms on cell cycle arrest and apoptotic induction of MCS-C2 in human lung cancer A549 cells. To investigate the effects of MCS-C2 on cell cycle progression in A549 cells, we measured DNA content of A549 cells treated with 5 microM of HY253 using flow cytometric analysis. The flow cytometric analysis revealed an appreciable G(2) phase arrest in A549 cells treated with 5 micronM of MCS-C2. This MCS-C2-induced G(2) phase arrest is associated with significant up-regulation of p53 and p21(Cip1) in A549 cells. Furthermore, TUNEL assay was used to examine apoptotic induction in A549 cells treated with 5 microM of MCS-C2 for 48 h. In addition, the effects of MCS-C2 on apoptosis-associated proteins in A549 cells were examined using Western blot analysis. The apoptotic induction in MCS-C2-treated A549 cells is associated with cytochrome c release from mitochondria which in turn resulted in the activation of caspase-9 and -3, and the cleavage of poly(ADP-ribose) polymerase (PARP). In conclusion, based on these results, we suggest that MCS-C2 may be a potent cancer chemotherapeutic candidate for use in treating human lung cancer cells via up-regulation and activation of p53.
Subject(s)
Apoptosis/drug effects , Cell Cycle/drug effects , Cytochromes c/metabolism , Lung Neoplasms/physiopathology , Toyocamycin/analogs & derivatives , Cell Line, Tumor , Humans , Lung Neoplasms/drug therapy , Lung Neoplasms/metabolism , Pyrimidine Nucleosides/pharmacology , Toyocamycin/pharmacologyABSTRACT
The synthesis of model 7 deazapurine derivatives related to tubercidin and toyocamycin has been performed. Tubercidin derivatives were obtained by simple conversion of the amino group of the heterocyclic moiety of the starting 7-deazadenosine compounds, into a hydroxyl group. Preparation of toyocamycin derivatives was accomplished by treatment of the silylated 6-bromo-5-cyanopyrrolo[2,3-d]pyrimidin-4-one with 1-O-acetyl-2,3,5-tri-O-benzoyl-beta-d-ribofuranose. The glycosylation reaction afforded a mixture of 8-bromo 7-cyano 2',3',5' tri-O-benzoyl 7-deazainosine and 6-bromo-5-cyano-3-(2',3',5'-tri-O-benzoyl-beta-d-ribofuranosyl)pyrrolo[2,3-d]-pyrimidin-4-one isomers: The structures were assigned on the basis of NMR spectroscopy studies. Next deprotection treatment gave the novel 7-deazainosine ribonucleosides.
Subject(s)
Inosine/analogs & derivatives , Pyrimidine Nucleosides/chemical synthesis , Antiviral Agents/chemical synthesis , Antiviral Agents/chemistry , Antiviral Agents/pharmacology , Drug Design , Inosine/chemical synthesis , Inosine/chemistry , Inosine/pharmacology , Magnetic Resonance Spectroscopy , Pyrimidine Nucleosides/chemistry , Pyrimidine Nucleosides/pharmacology , RNA Viruses/drug effects , RNA Viruses/physiology , Toyocamycin/analogs & derivatives , Toyocamycin/chemical synthesis , Toyocamycin/chemistry , Tubercidin/analogs & derivatives , Tubercidin/chemical synthesis , Tubercidin/chemistry , Virus Replication/drug effectsABSTRACT
Several Toyocamycin (4) analogues were examined for their ability to inhibit HCV RNA in a replicon assay. Among the compounds examined 4-methylthio (18) and 5-carboxamide oxime derivatives (23 and 27) of Toyocamycin were found to have good activity and selectivity.
Subject(s)
Antiviral Agents/chemical synthesis , Toyocamycin/chemical synthesis , Antiviral Agents/pharmacology , Hepatitis C/drug therapy , Hepatitis C/metabolism , Hepatitis C/virology , Humans , Magnetic Resonance Spectroscopy , Molecular Structure , Pyrimidine Nucleosides/chemistry , Pyrimidines/chemistry , Pyrroles/chemistry , RNA-Dependent RNA Polymerase/antagonists & inhibitors , RNA-Dependent RNA Polymerase/metabolism , Toyocamycin/analogs & derivatives , Toyocamycin/pharmacology , Viral Nonstructural Proteins/antagonists & inhibitors , Viral Nonstructural Proteins/metabolismABSTRACT
The purpose of the present study was to investigate the mechanisms involved in the antiproliferative and apoptotic effects of MCS-C2, a novel analog of the pyrrolo[2,3-d]pyrimidine nucleoside toyocamycin and sangivamycin, in human prostate cancer LNCaP cells. MCS-C2, a selective inhibitor of cyclin-dependent kinase, was found to inhibit cell growth in a time- and dose-dependent manner, and inhibit cell cycle progression by inducing the arrest of the G1 phase and apoptosis in LNCaP cells. When treated with 3 microM MCS-C2, inhibited proliferation associated with apoptotic induction was found in the LNCaP cells in a concentration and time-dependent manner, and nuclear DAPI staining revealed the typical nuclear features of apoptosis. Furthermore, MCS-C2 induced cell cycle arrest in the G1 phase through the upregulated phosphorylation of the p53 protein at Ser-15 and activation of its downstream target gene p21WAF1/CIP1. Accordingly, these results suggest that MCS-C2 inhibits the proliferation of LNCaP cells by way of G1-phase arrest and apoptosis in association with the regulation of multiple molecules in the cell cycle progression.
Subject(s)
Antineoplastic Agents/pharmacology , Apoptosis/drug effects , Cell Cycle/drug effects , Cyclin-Dependent Kinases/antagonists & inhibitors , Prostatic Neoplasms/drug therapy , Signal Transduction/drug effects , Toyocamycin/analogs & derivatives , Antineoplastic Agents/metabolism , Antineoplastic Agents/therapeutic use , Cyclin-Dependent Kinase Inhibitor p21/metabolism , Cyclin-Dependent Kinases/metabolism , Dose-Response Relationship, Drug , Humans , Male , Phosphorylation , Prostatic Neoplasms/metabolism , Prostatic Neoplasms/pathology , Serine/metabolism , Toyocamycin/metabolism , Toyocamycin/pharmacology , Toyocamycin/therapeutic use , Tumor Cells, Cultured , Tumor Suppressor Protein p53/metabolism , Up-RegulationABSTRACT
The purpose of the present study was to investigate the anti-proliferative and apoptotic effects of MCS-C2, a novel synthetic analogue of the pyrrolo[2,3-d]pyrimidine nucleoside toyocamycin and sangivamycin, in human promyelocytic leukemia (HL-60) cells. When treated with 5 microM MCS-C2, inhibited proliferation associated with apoptotic induction was found in the HL-60 cells in a concentration-dependent and time-dependent manner, plus nuclear DAPI staining revealed the typical nuclear features of apoptosis. However, MCS-C2 showed almost no antiproliferative effect and no apoptotic induction in normal lymphocyte cells used as a control when compared with those in HL-60 cancer cells. Moreover, a flow cytometric analysis of the HL-60 cells using FITC-dUTP and propidium iodide (PI) showed that the apoptotic cell population increased gradually from <1% at 0 h to 34% at 12 h after exposure to 5 microM MCS-C2. This apoptotic induction was associated with the cleavage of Bid and a release of cytochrome c from mitochondria into the cytosol, followed by the activation of caspase-3 and inactivation of poly(ADP-ribose) polymerase (PARP). However, there was no significant change in any other mitochondrial membrane proteins, such as Bcl-2 and Bax. Consequently, the current findings suggest that the mitochondrial pathway was primarily involved in the MCS-C2-induced apoptosis in the human promyelocytic leukemia HL-60 cells.
Subject(s)
Apoptosis/drug effects , Cell Proliferation/drug effects , Toyocamycin/analogs & derivatives , Toyocamycin/pharmacology , Caspase 3 , Caspases/metabolism , Cytochromes c/metabolism , HL-60 Cells , Humans , Kinetics , MitochondriaABSTRACT
Coupling reaction of 2-beta-C-methyl-1,2,3,4-tetra-O-benzoyl-d-ribofuranose with 4-amino-6-bromo-5-cyanopyrrolo[2,3-d]pyrimidine, followed by debromination and debenzoylation, gave the 2'-beta-C-methyl toyocamycin in high yield. Based on this result, a series of 2'-beta-C-methyl-4-substituted toyocamycin and sangivamycin analogues were synthesized for biological screening as potential inhibitors of HCV RNA replication.
Subject(s)
Antiviral Agents/chemical synthesis , Hepacivirus , Pyrimidine Nucleosides/chemical synthesis , Toyocamycin/analogs & derivatives , Adenosine/analogs & derivatives , Adenosine/chemical synthesis , Replicon/drug effects , Structure-Activity Relationship , Toyocamycin/chemical synthesisABSTRACT
Syntheses and antiviral activity of new carbocyclic analogs of 2', 3'-dideoxysangivamycin, 2',3'-dideoxytoyocamycin and 2',3'-dideoxytriciribine is described. The key intermediate, carbocyclic 4-chloro-5-iodopyrrolopyrimidine. was synthesized in good yield via a novel iodination method using I2 and CF3COOAg. This carbocyclic 4-chloro-5-iodopyrrolopyrimidine then allowed for a concise synthesis of the desired 4,5-disubstituted carbocyclic nucleosides.
Subject(s)
Antiviral Agents/chemical synthesis , Pyrimidine Nucleosides/chemical synthesis , Ribonucleosides/chemical synthesis , Toyocamycin/analogs & derivatives , Toyocamycin/chemical synthesis , Antiviral Agents/pharmacology , Deoxyribonucleosides/metabolism , Deoxyribonucleosides/pharmacology , Magnetic Resonance Spectroscopy , Models, Chemical , Toyocamycin/pharmacologyABSTRACT
Syntheses of pyrrolo[2,1-f][1,2,4]triazine C-nucleosides are reported. Treatment of pyranulose glycoside with aminoguanidine in acetic acid gave the corresponding semicarbazone in 96% yield. The ring transformation of the semicarbazone in dioxane afforded a 51% yield of 2-amino-7-(2,3,5-tri-O-benzoyl-beta-D-ribofuranosyl)pyrrolo[2,1-f]-[1,2,4]triazine. Vilsmeier formylation of the pyrrolotriazine gave the major product, 5-formylpyrrolo[2,1-f][1,2,4]triazine, in 69% yield. The aldehyde was treated with hydroxylamine hydrochloride in methanol to give aldoximes. Dehydration of aldoxime with trifluoromethanesulfonic anhydride and triethylamine in dichloromethane afforded 5-cyanopyrrolo[2,1-f][1,2,4]triazine in 44% yield. Conversion of the nitrile to the deprotected amide, 2-amino-7-(beta-D-ribofuranosyl)pyrrolo[2,1-f][1,2,4]triazine-5-carboxamide, was accomplished in 96% yield on treatment with 30% H2O2 in ethanol for 1 day at room temperature. Debenzoylation with sodium hydroxide solution produced deprotected C-nucleosides.
Subject(s)
Antibiotics, Antineoplastic/chemical synthesis , Pyrimidine Nucleosides/chemical synthesis , Ribonucleosides/chemical synthesis , Toyocamycin/analogs & derivatives , Toyocamycin/chemical synthesis , Triazines/chemical synthesis , Tubercidin/analogs & derivatives , Tubercidin/chemical synthesis , Antibiotics, Antineoplastic/chemistry , Indicators and Reagents , Ribonucleosides/chemistry , Spectrometry, Mass, Fast Atom Bombardment , Stereoisomerism , Toyocamycin/chemistry , Triazines/chemistry , Tubercidin/chemistryABSTRACT
Toyocamycin and some analogues have shown potent antitumor activities; however, none of them could be used clinically primarily owing to their cytotoxicity to normal human cells. In order to overcome the weakness of these nucleoside analogues, substitution of a variety of modified sugars for the ribofuranose was explored in our laboratories with expectation that certain sugar-modified toyocamycin analogues may be selectively cytotoxic to cancer cells. In this article, we report synthesis and cytotoxicity of 4'-C- and 5'-C-substituted toyocamycins, which were prepared via the condensations of 4-C- and 5-C-substituted ribofuranose derivatives 11, 12, 13, 20, 21, and 26 with the silylated form of 4-amino-6-bromo-5-cyanopyrrolo[2,3-]pyrimidine (27) and subsequent debromination and debenzoylation. When compared to the parent toyocamycin, all these analogues showed much lower cytotoxicity to human prostate cancer cells (HTB-81), mouse melanoma cancer cells (B16) as well as normal human fibroblasts. Compound 1e showed a significant cytotoxicity to the prostate cancer cells and a moderate selectivity. The results suggested that sugar modifications, especially those that may affect phosphorylation of nucleosides, could alter cytotoxicity profile significantly.
Subject(s)
Cytotoxins/chemical synthesis , Toyocamycin/analogs & derivatives , Animals , Cell Line/drug effects , Cytotoxins/pharmacology , Humans , Mice , Models, Chemical , Toyocamycin/chemical synthesis , Toyocamycin/pharmacology , Tumor Cells, Cultured/drug effectsABSTRACT
A number of 7-substituted 4-aminopyrrolo[2,3-d]pyrimidine-5-carbonitrile, -5-carboxamide, and -5-thiocarboxamide derivatives related to the nucleoside antibiotics toyocamycin and sangivamycin were prepared and tested for their activity against human cytomegalovirus (HCMV) and herpes simplex virus type-1 (HSV-1). Treatment of 2-amino-5-bromo-3,4-dicyanopyrrole (1) with triethyl orthoformate followed by alkylation via the sodium salt method with a variety of alkylating agents furnished the corresponding 1-substituted pyrroles 2a-k. Ring annulation was achieved with methanolic ammonia affording the 7-substituted 4-amino-6-bromopyrrolo++-[2,3-d]pyrimidine-5-carbonitrile derivatives 3a-k. Debromination of 3a-k, via catalytic hydrogenation, gave the corresponding 7-substituted 4-aminopyrrolo[2,3-d]pyrimidine-5-carbonitrile analogs 4a-j,l. A selective reduction of 4-amino-6-bromo-7-allylpyrrolo[2,3-d]-pyrimidine-5-carbon ril e (3k) in zinc and acetic acid furnished 4-amino-7-allylpyrrolo-[2,3-d]pyrimidine-5-carbonitrile (4k). Conventional functional group transformations involving the 5-cyano group of 4 furnished the 5-carboxamide derivatives 5a-1 and the 5-thio-amide analogs 6a-l. A similar transformation of the aglycone of toyocamycin (4m) furnished the corresponding aglycone of thiosangivamycin (6m). Several of the new compounds (4-6a-ej-l) were evaluated for their ability to inhibit the growth of L1210 murine leukemic cells. Whereas a number of the carboxamide (5) and thioamide (6) derivatives had modest activity, the corresponding nitrile analogs (4) were all inactive. All compounds were tested for activity against HCMV and HSV-1. The non-nucleoside nitrile analogs 4a-m and carboxamide derivatives 5a-l were, with a few exceptions, essentially inactive against HCMV and HSV-1 and relatively nontoxic. In direct contrast, nearly all of the thioamide derivates 6a-1, including the aglycone of thiosangivamycin (6m), were good inhibitors of HCMV and HSV-1. Most were noncytotoxic in their antiviral concentration range. Cytotoxicity which was observed appeared to be a consequence of DNA synthesis inhibition. Several of these compounds, such as 6b,e, were particularly interesting inhibitors of HCMV with IC(50)'s ranging from 0.1 to 1.3 muM. The antiviral activity of both compounds was well separated from cytotoxicity in KB, HFF, and L1210 cells.
Subject(s)
Antiviral Agents/chemical synthesis , Pyrimidine Nucleosides/chemical synthesis , Pyrimidines/chemical synthesis , Toyocamycin/analogs & derivatives , Toyocamycin/chemical synthesis , Antiviral Agents/pharmacology , Cell Survival/drug effects , Cells, Cultured , Cytomegalovirus/drug effects , Fibroblasts , Herpesvirus 1, Human/drug effects , Humans , Indicators and Reagents , Magnetic Resonance Spectroscopy , Male , Microbial Sensitivity Tests , Molecular Structure , Pyrimidine Nucleosides/pharmacology , Pyrimidines/pharmacology , Skin , Structure-Activity Relationship , Thionucleosides/chemical synthesis , Thionucleosides/pharmacology , Toyocamycin/pharmacology , Viral Plaque AssayABSTRACT
Non-nucleoside analogs of the pyrrolopyrimidine nucleosides toyocamycin, sangivamycin and thiosangivamycin have been synthesized and their cytotoxicity in mammalian cells determined. While studying the effects of 5-thioamide-substituted analogs on cell growth, we observed an interesting phenomenon in which cells recovered spontaneously from growth inhibition during extended incubations. HPLC studies demonstrated that the 5-thioamide moiety of several structurally dissimilar 7-substituted 4-aminopyrrolo[2,3-d]pyrimidines, including thiosangivamycin, is unstable in cell culture medium and is converted to the corresponding 5-nitrile with a half-life of approximately 48 h. In contrast, different substituents at the 4-position of the heterocycle significantly affected the stability of the 5-thioamide moiety. Conversion of the thioamide to the nitrile was caused by components in the cell culture medium, not components of serum. The above observations demonstrate that caution should be exercised in interpreting biological data obtained in vitro for 5-thioamide pyrrolo[2,3-d]pyrimidines.
Subject(s)
Antibiotics, Antineoplastic/toxicity , Thionucleosides/toxicity , Toyocamycin/toxicity , Cell Division/drug effects , Culture Media/chemistry , Humans , Structure-Activity Relationship , Thionucleosides/chemical synthesis , Thionucleosides/chemistry , Toyocamycin/analogs & derivatives , Tumor Cells, CulturedABSTRACT
The structures of five naturally-occurring herbicidal nucleosides have been determined by spectral analysis. Three (5'-deoxyguanosine, coaristeromycin and 5'-deoxytoyocamycin) are novel natural products while the remaining two (coformycin and adenine 9-beta-D-arabinofuranoside) are known natural products which have not previously been reported to be herbicidal.
Subject(s)
Actinomycetales/metabolism , Deoxyguanosine/analogs & derivatives , Herbicides/chemistry , Inosine/analogs & derivatives , Nucleosides/chemistry , Toyocamycin/analogs & derivatives , Chromatography, High Pressure Liquid , Coformycin/chemistry , Coformycin/isolation & purification , Deoxyguanosine/chemistry , Deoxyguanosine/isolation & purification , Fermentation , Herbicides/isolation & purification , Inosine/chemistry , Inosine/isolation & purification , Magnetic Resonance Spectroscopy , Molecular Structure , Nucleosides/isolation & purification , Purine Nucleosides/chemistry , Purine Nucleosides/isolation & purification , Toyocamycin/chemistry , Toyocamycin/isolation & purification , Vidarabine/chemistry , Vidarabine/isolation & purificationABSTRACT
Protection of the 3'- and 5'-hydroxyl groups of the nucleoside antibiotic toyocamycin (1) with 1,3-dichloro-1,1,3,3-tetraisopropyldisiloxane was followed by (trifluoromethyl)sulfonylation of the 2'-hydroxyl group. A displacement of the resulting triflate ester moiety with lithium chloride, lithium bromide, sodium iodide, and lithium azide in hexamethylphosphoramide was followed by a removal of the disilyl moiety with tetra-n-butylammonium fluoride to afford the appropriate (2'-deoxy-2'-substituted-arabinofuranosyl)toyocamycin analogues 6a-d. Hydrolysis of the carbonitrile moieties of 6a-d with hydrogen peroxide gave the corresponding sangivamycin analogues (7a-d). A reduction of the azido moiety of 6a and 7a with 1,3-propanedithiol furnished the corresponding amino derivatives (6e and 7e). The antiproliferative activity of 6a-e and 7a-e was evaluated in L1210 cell cultures. None of these compounds caused significant inhibition of cell growth. Evaluation of these compounds for antiviral activity showed that all the toyocamycin analogues were active against human CMV, but of the sangivamycin analogues, only (2'-deoxy-2'-azidoarabinosyl)sangivamycin (7a) was active against this virus. None of the compounds were active against HSV-1 or HSV-2. (2'-Deoxy-2'-aminoarabinofuranosyl)toyocamycin (6e) was studied more extensively and showed some separation between antiviral activity and cytotoxicity as measured by effects on DNA synthesis, cell growth, and cell-plating efficiency. Although 6e also was active against murine CMV in vitro, it was not active against this virus in infected mice. We conclude that arabinosylpyrrolopyrimidines have potential as antivirals, but no members of the current series are potent enough to show significant activity in vivo.
Subject(s)
Antiviral Agents/pharmacology , Arabinonucleosides/pharmacology , Cytomegalovirus Infections/drug therapy , Cytomegalovirus/drug effects , Pyrimidine Nucleosides/pharmacology , Toyocamycin/analogs & derivatives , Animals , Antiviral Agents/chemical synthesis , Antiviral Agents/therapeutic use , Arabinonucleosides/chemical synthesis , Arabinonucleosides/therapeutic use , Cell Division/drug effects , Chemical Phenomena , Chemistry , Humans , Leukemia L1210/pathology , Mice , Molecular Structure , Pyrimidine Nucleosides/chemical synthesis , Pyrimidine Nucleosides/therapeutic use , Simplexvirus/drug effects , Structure-Activity Relationship , Toyocamycin/chemical synthesis , Toyocamycin/pharmacology , Toyocamycin/therapeutic use , Tumor Cells, CulturedABSTRACT
The sodium salt of 4-amino-3-cyanopyrazolo[3,4-d]pyrimidine (1) was condensed with (2-acetoxyethoxy)methyl bromide (2) to provide the corresponding protected acyclic nucleoside, 4-amino-3-cyano-1-[(2-acetoxyethoxy)methyl]-pyrazolo[3,4-d]pyrimid ine (3). Treatment of 3 with sodium methoxide in methanol provided a good yield of methyl 4-amino-1-[(2-hydroxyethoxy)methyl]pyrazolo[3,4-d]pyrimidine-3- formimidate (4). Treatment of the imidate (4) with sodium hydrogen sulfide gave the thiocarboxamide derivative 5. Aqueous base transformed 4 into 4-amino-1-[(2-hydroxyethoxy)methyl]pyrazolo[3,4-d]pyrimidine-3- carboxamide (6) in good yield. Treatment of 5 with mercuric chloride furnished the toyocamycin analogue 7. Evaluation of compounds 1, 3-7 revealed that only the heterocycle (1) and the thiocarboxamide acyclic nucleoside (5) were active. Compound 5 was the more potent with activity against human cytomegalovirus and herpes simplex virus type 1.
Subject(s)
Anti-Bacterial Agents/chemical synthesis , Antiviral Agents/chemical synthesis , Cytomegalovirus/drug effects , Pyrimidine Nucleosides/chemical synthesis , Simplexvirus/drug effects , Toyocamycin/chemical synthesis , Aminoglycosides , Animals , Cell Line , Cell Survival/drug effects , Cytomegalovirus/growth & development , Dose-Response Relationship, Drug , Humans , Indicators and Reagents , KB Cells , Molecular Structure , Pyrimidine Nucleosides/pharmacology , Simplexvirus/growth & development , Structure-Activity Relationship , Toyocamycin/analogs & derivatives , Toyocamycin/pharmacology , Viral Plaque AssayABSTRACT
A number of 7-[(2-hydroxyethoxy)methyl]pyrrolo[2,3-d]pyrimidine derivatives related to the nucleoside antibiotics toyocamycin and sangivamycin were prepared and tested for their biological activity. Treatment of the sodium salt of 4-amino-6-bromo-5-cyanopyrrolo[2,3-d]pyrimidine (1) with (2-acetoxyethoxy)methyl bromide (2) afforded a mixture of 4-amino-6-bromo-5-cyano-7-[(2-acetoxyethoxy)methyl]pyrrolo[2,3-d] pyrimidine (3) and the corresponding N1 isomer. Debromination of this mixture gave the corresponding 4-amino-5-cyano-7-[(2-acetoxyethoxy)-methyl]pyrrolo[2,3-d]pyrimidi ne (4) and 4-amino-5-cyano-1-[(2-acetoxyethoxy)methyl]pyrrolo[2,3-d]pyrimidin e (5). Deacetylation of 4 and 5 furnished 4-amino-5-cyano-7-[(2-hydroxyethoxy)methyl]pyrrolo[2,3-d]pyrimidine (6) and the corresponding N1 isomer (7), respectively. The sites of attachment for the acyclic moiety for 6 and 7 were assigned on the basis of UV spectral studies as well as 13C NMR spectroscopy. Conventional functional group transformation of 6 provided a number of novel 5-substituted derivatives (8-10), including the sangivamycin derivative 8. The methyl formimidate derivative 10 was converted to the thioamide derivative 11 and the carbohydrazide derivative 12. Compounds 6 and 8-12 were tested for cytotoxicity to L1210 murine leukemic cells in vitro. None of these compounds caused significant inhibition of cell growth. Evaluation of compounds 4 and 6-12 for activity against human cytomegalovirus (HCMV) and herpes simplex virus type 1 (HSV-1) revealed that only the thioamide (11) was active. It inhibited HCMV but not HSV-1 at concentrations producing only slight cytotoxicity in human foreskin fibroblasts (HFF cells) and KB cells.
Subject(s)
Anti-Bacterial Agents/pharmacology , Antiviral Agents , Cell Survival/drug effects , Pyrimidine Nucleosides/pharmacology , Pyrroles/pharmacology , Toyocamycin/pharmacology , Aminoglycosides , Animals , Cells, Cultured , Chemical Phenomena , Chemistry , Haplorhini , Humans , Mice , Pyrimidine Nucleosides/chemical synthesis , Pyrroles/chemical synthesis , Toyocamycin/analogs & derivativesABSTRACT
Treatment of 7-amino-3-beta-D-ribofuranosylpyrazolo[4,3-d]pyrimidine (formycin) with alpha-acetoxyisobutyryl bromide followed by deprotection of the resulting trans-vicinal acetoxy bromides and hydrogenolysis of the separated bromohydrins gave 2'-deoxy-(23%) and 3'-deoxyformycin (32%) after complete deprotection and purification of their hydrochloride salts. An analogous sequence gave 3'-deoxytoyocamycin and/or 3'-deoxysangivamycin in approximately 80% yields from toyocamycin. Antiviral, antineoplastic, and antimetabolic effects were evaluated for the formycin compounds and 4-amino-7-beta-D-ribofuranosylpyrrolo[2,3-d]pyrimidine (tubercidin), its 5-cyano- (toyocamycin), and 5-carbamoyl-(sangivamycin) antibiotic congeners in comparison with their 2'-deoxy, 3'-deoxy, and arabino analogues. In all cases, the modified-sugar compounds were less cytotoxic than the parent antibiotics. The majority also exhibited lower antiviral potency. However, the xylo-tubercidin analogue retained potent antiherpes 1 and 2 activity with decreased cytotoxicity. Labeled metabolite studies suggested that effects of these compounds on RNA and/or protein synthesis might be more significant than interference with DNA synthesis.
Subject(s)
Antibiotics, Antineoplastic/chemical synthesis , Antiviral Agents/chemical synthesis , Formycins/chemical synthesis , Ribonucleosides/chemical synthesis , Toyocamycin/chemical synthesis , Tubercidin/chemical synthesis , Animals , Formycins/pharmacology , Leukemia L1210/pathology , Mice , Microbial Sensitivity Tests , Pyrimidine Nucleosides/chemical synthesis , Pyrimidine Nucleosides/pharmacology , Structure-Activity Relationship , Toyocamycin/analogs & derivatives , Toyocamycin/pharmacology , Tubercidin/analogs & derivatives , Tubercidin/pharmacologySubject(s)
Antibiotics, Antineoplastic/pharmacology , Deoxyribonucleotides/pharmacology , Formycins/pharmacology , Ribonucleosides/pharmacology , Ribonucleotide Reductases/antagonists & inhibitors , Toyocamycin/pharmacology , Tubercidin/pharmacology , Binding Sites , Cytidine Triphosphate/metabolism , Formycins/chemical synthesis , Kinetics , Toyocamycin/analogs & derivatives , Toyocamycin/chemical synthesis , Tubercidin/analogs & derivatives , Tubercidin/chemical synthesisABSTRACT
The 6-aza analogues of toyocamycin and sangivamycin were prepared as potential cytotoxic agents. The toyocamycin analogue (4-amino-1-(beta-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine-3-carbonitrile) could not be obtained directly from its O-acetylated precursor but was accessible via 4-amino-1-(beta-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine-3-thiocarboxamide. The identity of the nitrile was verified by its ultraviolet, infrared, and mass spectra, and by its conversion to the corresponding 3-carboxamide and thiocarboxamide when treated with water or hydrogen sulfide, respectively. Bioassay of the synthetic compounds in comparison with 4-amino-1-(beta-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine (6-azatubercidin) and 4-amino-2-(beta-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine revealed that the 3-thiocarboxamido derivative was more cytotoxic to the growth of mouse fibroblasts than 6-azatubercidin, effecting killing of 3T6 cells at less than or equal to 1 mug/ml. 4-Amino-1-(beta-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine (but not its 2-ribofuranosyl isomer) was shown to act as a substrate for adenosine deaminase from calf intestinal mucosa with an apparent Km of 125 (vs. 20 for adenosine) and the corresponding 5'-diphosphate of 6-azatubercidin was polymerized by polynucleotide phosphorylase (Micrococcus luteus) in the presence of Mn2+ to afford a homopolymer and copolymers with adenosine. The copolymers directed the binding of [3H]lysyl-tRNA to the A-site of ribosomes from Escherichia coli, but could not be used for the synthesis of polylsine in a cellfree system. The copolymer consiting of adenosine and 6-azatubercidin in a 2:1 ratio was found to form a 1:1 complex with poly(uridylic acid) at 4degreesC.